08.08.17
SGS, a bio/pharmaceutical analytical and bioanalytical contract services provider, is expanding its facility in Lincolnshire, IL. The expansion will increase the site’s current footprint from 38,500 sq.-ft. to nearly 58,000 sq.- ft. and is scheduled to be completed by September 2017.
The expansion will allow the facility to increase capacity for a wide range of services, including analytical method development and testing, microbiological evaluation, drug stability studies, testing of containers and medical devices, and utilities qualification and monitoring. Additional staff will be employed to meet the demands on the lab.
“This investment allows us to be flexible in our approach to meeting both existing and future customer demands,” said James Nokes, vice president, U.S. Agriculture, Food and Life. “Analysis and bioanalysis techniques continue to evolve rapidly, and are driven by technological advances and regulatory needs. At SGS, it is our aim to ensure we can offer our clients integrated solutions to support their needs, so we continue to invest in capabilities, capacity and our staff to maintain our professionalism and efficiency.”
This expansion follows a series of recent investments at the company’s global lab network, including increases in extractables and leachables capabilities in Fairfield, NJ and Shanghai, China; and an investment in bioanalytical capabilities and elemental analysis in Poitiers and Villeneuve-la-Garenne, respectively.
The expansion will allow the facility to increase capacity for a wide range of services, including analytical method development and testing, microbiological evaluation, drug stability studies, testing of containers and medical devices, and utilities qualification and monitoring. Additional staff will be employed to meet the demands on the lab.
“This investment allows us to be flexible in our approach to meeting both existing and future customer demands,” said James Nokes, vice president, U.S. Agriculture, Food and Life. “Analysis and bioanalysis techniques continue to evolve rapidly, and are driven by technological advances and regulatory needs. At SGS, it is our aim to ensure we can offer our clients integrated solutions to support their needs, so we continue to invest in capabilities, capacity and our staff to maintain our professionalism and efficiency.”
This expansion follows a series of recent investments at the company’s global lab network, including increases in extractables and leachables capabilities in Fairfield, NJ and Shanghai, China; and an investment in bioanalytical capabilities and elemental analysis in Poitiers and Villeneuve-la-Garenne, respectively.
